Invention Grant
- Patent Title: MTA-cooperative PRMT5 inhibitors
-
Application No.: US17018738Application Date: 2020-09-11
-
Publication No.: US11492351B2Publication Date: 2022-11-08
- Inventor: Thomas P. Bobinski , Christopher Ronald Smith , Matthew Arnold Marx , John Michael Ketcham , Aaron Craig Burns , John David Lawson , Svitlana Kulyk , Jon Kuehler , Anthony Ivetac
- Applicant: Mirati Therapeutics, Inc.
- Applicant Address: US CA San Diego
- Assignee: Mirati Therapeutics, Inc.
- Current Assignee: Mirati Therapeutics, Inc.
- Current Assignee Address: US CA San Diego
- Agency: McDonnell Boehnen Hulbert & Berghoff LLP
- Main IPC: C07D471/04
- IPC: C07D471/04 ; C07D237/32 ; C07D401/10 ; C07D403/10 ; C07D403/12 ; C07D413/10 ; C07D413/14 ; C07D417/10 ; C07D401/14 ; C07D487/04 ; C12N9/10
Abstract:
The present invention relates to compounds that inhibit Protein Arginine N-Methyl Transferase 5 (PRMT5) activity. In particular, the present invention relates to compounds of Formula (I) to pharmaceutical compositions comprising compounds of Formula (I) and to methods of use thereof, such as methods of treating cancer using the compounds of Formula (I) and pharmaceutical compositions comprising those compounds.
Public/Granted literature
- US20210079003A1 MTA-Cooperative PRMT5 Inhibitors Public/Granted day:2021-03-18
Information query
